RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 1-11
  • U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug

    Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000 per treatment course, raising renewed concerns over the high costs to taxpayers. In a letter sent Friday, Ron Wyden (D-Ore.)...
  • New drugs provide cure for hepatitis C, research finds

    Twenty-five years after scientists first identified the hepatitis C virus, doctors are declaring victory over an infection that afflicts more than 3 million Americans and kills more of them than HIV. In a series of clinical trial results, a new...
  • AbbVie profit jumps 7% on strong Humira sales

    AbbVie profit jumps 7% on strong Humira sales
    AbbVie Inc. posted better-than-expected first-quarter earnings on Friday, propelled by another strong quarter of sales of the blockbuster drug Humira. The North Chicago-based pharmaceutical company said Friday that revenue rose 5.4 percent to $4.56...
  • The $84,000 hepatitis drug [Letter]

    It was interesting to read that there is now a cure for hepatitis C in the form of new drugs that are capable of completely suppressing the virus in 90 percent of patients in 8 to 12 weeks ("Gilead Sciences' $84,000 price for hepatitis drug is...
  • Obamacare enrollment nears 1.4 million in California exchange

    Obamacare enrollment nears 1.4 million in California exchange
    Covered California signed up more than 200,000 consumers for Obamacare coverage after extending its enrollment deadline by two weeks, bringing the statewide total to nearly 1.4 million people. The health insurance exchange gave people until Tuesday to...
  • GLCCB to host forum on pre-exposure HIV treatment for at-risk populations

    GLCCB to host forum on pre-exposure HIV treatment for at-risk populations
    Local medical professionals will gather with members of Baltimore's gay community later this month to discuss a new medical treatment that involves HIV-negative patients taking a daily pill to avoid becoming infected. The April 28 forum, hosted by the...
  • Nasdaq plunges on tech stock sell-off

     Nasdaq plunges on tech stock sell-off
    A plunge in once-soaring technology shares sent Nasdaq into a triple-digit decline and yanked the rest of the stock market down with it. Erstwhile darlings such as Netflix Inc. and Facebook Inc., as well as biotechnology highfliers such as Intercept...
  • U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price

    U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price
    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company Thursday, Rep....
  • Gilead Sciences' $84,000 price for hepatitis drug is scrutinized

    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A....
  • Prices of new hepatitis C drugs are tough to swallow for insurers

    A pair of new drugs to treat hepatitis C offer a cure for millions of Americans afflicted with the disease — but at a potentially staggering cost to taxpayers and health plans. Until now, therapies for hepatitis C helped only about half of...
  • Health Insurers Propose Rate Increases For 2015 Coverage

    Insurance companies selling health plans next fall for coverage in 2015 are asking state regulators to approve prices that reflect medical-cost inflation, and, in some cases, federal mandates, and expensive drugs to treat Hepatitis C. Anthem Blue Cross...